BICYCLE THERAPEUTICS PLC - 8-K Filing

Bicycle Therapeutics reports Q3 2026 net loss of $10.5 million and announces FDA Orphan Drug Designation for nuzefatide pevedotin in pancreatic cancer. (Items: 2.02 Results of Operations and Financial Condition On October 29, 2026, Bicycle Therapeutics plc issued a press release announcing financial resul, 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No)

SEC EDGAR · October 29, 2026, 11:07 UTC

Tickers: $BCYC

Read the full article at SEC EDGAR

More Regulatory news

AMTECH SYSTEMS INC - 8-K Filing SEC EDGAR · November 12, 2026, 15:16 UTC
REGIONAL HEALTH PROPERTIES, INC - 8-K Filing SEC EDGAR · November 12, 2026, 15:09 UTC
Bitwise Avalanche ETF - 8-K Filing SEC EDGAR · November 12, 2026, 15:06 UTC
MiNK Therapeutics, Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 15:05 UTC
Future Vision II Acquisition Corp. - 10-Q Filing SEC EDGAR · November 12, 2026, 15:00 UTC
THUNDER MOUNTAIN GOLD INC - 10-Q Filing SEC EDGAR · November 12, 2026, 15:00 UTC
MiNK Therapeutics, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 14:49 UTC
SusGlobal Energy Corp. - 10-Q Filing SEC EDGAR · November 12, 2026, 14:42 UTC
Ideal Power Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 14:25 UTC
DIGI INTERNATIONAL INC - 8-K Filing SEC EDGAR · November 12, 2026, 14:23 UTC